Quick Summary

Boswellia serrata, a tree native to West Asia and North Africa, produces a resin rich in boswellic acids, compounds that have been studied for their anti-inflammatory properties. Clinical research has primarily investigated Boswellia extracts in conditions such as osteoarthritis, type 2 diabetes mellitus, radiation-induced cerebral edema, and intestinal dysbiosis. Evidence suggests Boswellia may improve joint function and reduce pain symptoms in mild to moderate knee osteoarthritis, with overall favorable safety profiles. It is also being explored as a potential adjunct treatment in various inflammatory and pain-related disorders, though challenges remain regarding product quality and formulation.

What is it?

Boswellia serrata is a tree species that produces a fragrant resin commonly known as Indian frankincense. This resin contains boswellic acids—bioactive compounds considered responsible for many of its purported therapeutic effects. Boswellia extracts are available as supplements in various standardized forms and are traditionally used in herbal medicine systems.

Traditional Uses

  • Used in traditional Ayurvedic and herbal medicine for inflammation-related conditions.
  • Commonly applied for managing joint pain, arthritis, and respiratory ailments.
  • Historically utilized to promote digestive health and alleviate intestinal discomfort.

Active Compounds

The primary active constituents in Boswellia resin are boswellic acids, including AKBA (acetyl-11-keto-β-boswellic acid), which have been studied for their potential anti-inflammatory and immunomodulatory effects.

Potential Benefits with Evidence Levels

Knee Osteoarthritis

Moderate Evidence: Several randomized controlled trials and systematic reviews, including meta-analyses, indicate that Boswellia serrata extracts may reduce pain and improve joint function in patients with mild to moderate knee osteoarthritis. For instance, standardized preparations like Aflapin® have demonstrated greater symptom improvement compared to placebo or other extracts. Despite promising results, study heterogeneity and the need for additional high-quality trials remain.

Type 2 Diabetes Mellitus

Low to Moderate Evidence: Meta-analyses suggest Boswellia supplementation may improve glycemic control by reducing HbA1C levels and favorably modulating lipid profiles (total cholesterol, triglycerides, LDL cholesterol). However, effects on fasting glucose levels were not statistically significant, and further research is required to confirm these findings.

Radiation-Induced Cerebral Edema and Necrosis

Limited Human Evidence: A meta-narrative review of small clinical studies (totaling approximately 130 patients) reported that Boswellia might reduce cerebral edema and radiation necrosis, potentially aiding corticosteroid dose reduction. The evidence is preliminary and insufficient to draw firm conclusions.

Irritable Bowel Syndrome with Small Bowel Dysbiosis

Preliminary Evidence: One randomized controlled trial found that a lecithin-based formulation combining Boswellia and Curcuma longa, along with a low-FODMAP diet, reduced markers of intestinal dysbiosis (urinary indican), abdominal bloating, and pain more effectively than placebo plus diet. These findings require replication in larger studies.

Side Effects

  • Mild gastrointestinal discomfort is the most commonly reported side effect.
  • No serious adverse events have been documented in the clinical trials reviewed.

Drug Interactions

Current clinical data on drug interactions with Boswellia serrata are limited or insufficient. There is some uncertainty regarding potential interactions with medications metabolized via inflammatory or immune pathways. Cautious use is advised until more conclusive information becomes available.

Who Should Avoid It

  • Individuals with known allergies to Boswellia or similar resinous substances should avoid use.
  • People with severe liver or kidney impairments should exercise caution pending further safety evidence.
  • Use during pregnancy and breastfeeding is not recommended without medical supervision due to insufficient safety data.

Evidence Limitations

  • Variability in Boswellia extract formulations and dosages across studies.
  • Limited number of large-scale, high-quality randomized controlled trials.
  • Lack of long-term safety and comprehensive drug interaction data.
  • Underrepresentation of pregnant and breastfeeding populations in clinical research.
  • Predominance of preclinical and mechanistic studies; clinical confirmation is limited for many uses.

References

Last Reviewed

June 2024

Disclaimer

This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before starting any new supplement, especially if you have underlying health conditions or are taking other medications.